PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Oncology10.1159/0003204622010785-6356-360A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary TractNiki Karachaliou, Aris Polyzos, Nikolaos Kentepozidis, Stylianos Kakolyris, Nikolaos Ziras, Nikolaos Vardakis, Antonia Kalykaki, Georgia Milaki, Vassilis Georgoulias, Nikolaos Androulakishttps://www.karger.com/Article/Pdf/320462, https://www.karger.com/Article/Pdf/320462
Cancer Research and Treatment10.4143/crt.2017.52620185041324-1330Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract CancerChanghoon Yoo, Boram Han, Hyeong Su Kim, Kyu-pyo Kim, Deokhoon Kim, Jae Ho Jeong, Jae-Lyun Lee, Tae Won Kim, Jung Han Kim, Dae Ro Choi, Hong Il Ha, Jinwon Seo, Heung-Moon Chang, Baek-Yeol Ryoo, Dae Young Zanghttp://e-crt.org/upload/pdf/crt-2017-526.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.526, http://www.e-crt.org/upload/pdf/crt-2017-526.pdf
European Journal of Cancer Supplements10.1016/s1359-6349(05)80998-x200532199-200703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)https://api.elsevier.com/content/article/PII:S135963490580998X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S135963490580998X?httpAccept=text/plain
10.21203/rs.3.rs-2075157/v12022A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancerNaminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Yuji Morine, Kazuo Watanabe, Makoto Ueno, Tatsuya Ioka, Masashi Kanai, Shunsuke Kondo, Naohiro Okano, Kazuhiko Koikehttps://www.researchsquare.com/article/rs-2075157/v1, https://www.researchsquare.com/article/rs-2075157/v1.html
European Journal of Cancer Supplements10.1016/s1359-6349(05)80923-1200532177627 POSTER UFT/LV combined with oxaliplatin (TEGAFOX) or with irinotecan (TEGAFIRI) as first-line treatment for metastatic colorectal cancer patients (pts). results of a randomized phase II I.T.M.O. studyhttps://api.elsevier.com/content/article/PII:S1359634905809231?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905809231?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdx369.102201728v244-v245Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)C. Yoo, B. Han, K-P. Kim, H.S. Kim, J.H. Kim, H-M. Chang, B-Y. Ryoo, D.Y. Zanghttps://api.elsevier.com/content/article/PII:S0923753420379928?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420379928?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx369.102/19939391/mdx369.102.pdf
Cancer Chemotherapy and Pharmacology10.1007/s00280-007-0673-72008625849-855S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II studyJunji Furuse, Takuji Okusaka, Narikazu Boku, Shinichi Ohkawa, Akira Sawaki, Toshikazu Masumoto, Akihiro Funakoshihttp://link.springer.com/content/pdf/10.1007/s00280-007-0673-7.pdf, http://link.springer.com/article/10.1007/s00280-007-0673-7/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-007-0673-7
European Journal of Cancer Supplements10.1016/s1359-6349(05)81002-x200532200-201707 PUBLICATION Capecitabine, oxaliplatin and irinotecan combination: a first line treatment for metastasic colorectal cancer, preliminary results of a phase II studyhttps://api.elsevier.com/content/article/PII:S135963490581002X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S135963490581002X?httpAccept=text/plain
British Journal of Cancer10.1038/bjc.2013.479201310961420-1427S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysisS Y Kim, Y S Hong, E K Shim, S-Y Kong, A Shin, J Y Baek, K H Junghttp://www.nature.com/articles/bjc2013479.pdf, http://www.nature.com/articles/bjc2013479, http://www.nature.com/articles/bjc2013479.pdf
Annals of Oncology10.1016/s0923-7534(20)32487-x201223xi156A Prospective Multicenter Phase II Study of Cisplatin and Weekly Docetaxel as First-Line Treatment of Recurrent or Metastatic NAsopharyngeal Cancer (KCSG HN07-01)J.H. Jihttps://api.elsevier.com/content/article/PII:S092375342032487X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375342032487X?httpAccept=text/plain